Skip to main content

Table 3 Multivariate Cox proportional hazards regression analysis of MACEs

From: Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy

Model

PCSK9 1-SD increase

PCSK9 T1

PCSK9 T2

PCSK9 T3

Crude

1.92 (1.43–2.57)†

1.00 (Reference)

2.57 (0.90–7.33)

4.44 (1.62–12.18)†

Model 1

1.99 (1.46–2.68)†

1.00 (Reference)

2.76 (0.96–7.95)

4.85 (1.74–13.54)†

Model 2

1.95 (1.41–2.70)†

1.00 (Reference)

2.94 (1.00–8.63)

3.93 (1.35–11.42)*

Model 3

1.86 (1.29–2.69)*

1.00 (Reference)

3.36 (1.11–10.22)*

3.76 (1.16–12.27)*

Model 4

1.86 (1.31–2.65)*

1.00 (Reference)

3.30 (1.09–10.01)*

3.70 (1.16–11.82)*

  1. *p < 0.05; †p < 0.01
  2. Model 1 adjusted for age and sex; Model 2 adjusted for Model 1 plus body mass index, baseline statin use, prior coronary artery disease, hypertension, diabetes and current smoking; Model 3 adjusted for Model 2 plus low- and high-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, lipoprotein (a) and high sensitivity C-reactive protein; Model 4 adjusted for Model 3 plus genetic mutations. PCSK9, proprotein convertase subtilisin-kexin type 9; MACE: major adverse cardiovascular events